BioAdaptives (BDPT) 10-K 14 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	9 Months Ended
	Dec. 31, 2013	Mar. 31, 2014	Jun. 30, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'BIOADAPTIVES, INC.	'	'
Entity Central Index Key	'0001575142	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$0
Entity Common Stock, Shares Outstanding	'	12,041,667	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013
Current assets:	'
Cash	$18,609
Deposit	1,700
Marketable securities	100,000
Total assets	120,309
Current liabilities	'
Advance from Ferris Holding, Inc. - related party	31,839
Total current liabilities	31,839
Stockholders' deficit:	'
Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)	'
Common stock ($.0001 par value, 100,000,000 shares authorized; 12,041,667 shares issued and outstanding as of December 31, 2013)	1,204
Additional paid-in capital	205,545
Deficit accumulated during the development stage	18,279
Accumulated other comprehensive income (loss)	-100,000
Total stockholders' deficit	88,470
Total liabilities and stockholders' deficit	$120,309

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013
Statement of Financial Position [Abstract]	'
Preferred stock, par value	$0.00
Preferred stock, shares authorized	5,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, par value	$0.00
Common stock, shares authorized	100,000,000
Common stock, shares issued	12,041,667
Common stock, shares outstanding	12,041,667

Statements_Of_Operations

Statements Of Operations (USD $)	9 Months Ended
	Dec. 31, 2013
Income Statement [Abstract]	'
Revenue	'
Operating expenses:	'
General and administrative	8,505
Professional fees	10,274
Total operating expenses	18,779
Operating income (loss)	-18,779
Other income (expenses)	'
Other income	500
Total other income (expense)	500
Net loss	-18,279
Unrealized loss on marketable securities	-100,000
Other comprehensive income (loss)	-100,000
Comprehensive income (loss)	($118,279)
Basic loss per common share	$0
Basic weighted average common shares outstanding	10,569,499

Shareholders_Equity

Shareholders Equity (USD $)	Preferred Stock	Common Stock	Additional Paid-in Capital - Related party	Deficit Accumulated During The Development Stage	Accumulated Other Comprehensive Income (Loss)	Total
Balance, value at Apr. 18, 2013	'	'	'	'	'	'
Balance, shares at Apr. 18, 2013	'	'	'	'	'	'
Share-based compensation - related party, shares	'	10,000,000	'	'	'	'
Share-based compensation - related party, value	'	1,000	'	'	'	1,000
Contribution by Ferris Holding, Inc. - related party	'	'	749	'	'	749
Shares issued to Ferris Holding, Inc.for cash - related party, shares	'	41,667	'	'	'	'
Shares issued to Ferris Holding, Inc.for cash - related party, value	'	4	4,996	'	'	5,000
Asset purchase agreement, shares	'	2,000,000	'	'	'	'
Asset purchase agreement, value	'	200	199,800	'	'	200,000
Net change in unrealized gain (loss) marketable securities	'	'	'	'	-100,000	-100,000
Net loss	'	'	'	-18,279	'	-18,279
Balance, value at Dec. 31, 2013	'	$1,204	$205,545	($18,279)	($100,000)	$88,470
Balance, shares at Dec. 31, 2013	'	'	'	'	'	12,041,667

Statements_Of_Cash_Flows

Statements Of Cash Flows (USD $)	9 Months Ended
	Dec. 31, 2013
Statement of Cash Flows [Abstract]	'
Net loss	($18,279)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'
Stock-based compensation - related party	1,000
Changes in operating assets and liabilities:	'
Deposit	-1,700
Accounts payable and accrued liabilities	'
Net cash used in operating activities	-18,979
Cash flows from financing activities:	'
Proceeds from issuance of stock - related party	5,000
Proceeds from additional paid in capital - related party	749
Advances from related party	31,839
Net cash provided by financing activities	37,588
Net change in cash	18,609
Cash, beginning of period	'
Cash, end of period	18,609
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:	'
Cash paid for interest	'
Cash paid for taxes	'
Non-cash investing and financing activities:	'
Common stock issued for purchase of assets	$200,000

Description_Of_Business_And_Hi

Description Of Business And History	9 Months Ended
	Dec. 31, 2013
Description Of Business And History	'
Description Of Business And History	'
	1	DESCRIPTION OF BUSINESS AND HISTORY
	Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) (“BioAdaptives”) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.
	On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc (“Blenders”). Blenders is a 100% owned subsidiary incorporated in the State of Nevada. Blenders was created as a separate sales and marketing organization. BioAdaptives does not plan to sell or market products directly, instead seeking to use Blenders as its marketing arm.

Summary_Of_Significant_Policie

Summary Of Significant Policies	9 Months Ended
	Dec. 31, 2013
Summary Of Significant Policies	'
Summary Of Significant Policies	'
	2	SUMMARY OF SIGNIFICANT POLICIES
	Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”
	Use of estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S.GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.
	Cash and cash equivalents – Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high credit quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value.
	Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.
	In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Corporation. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.
	Revenue Recognition – Revenue is only recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the buyer is fixed or determinable, and (4) collectability is reasonably assured.
	Earnings (loss) per share – Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. There were no potentially dilutive securities outstanding during the periods presented.
	Stock-based compensation – The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Financial Accounting Standards Board (“FASB”) ASC 718-10, Compensation – Stock Compensation, and the conclusions reached by FASB ASC 505-50, Equity – Equity-Based Payments to Non-Employees. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.
	Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 (“ASC 820-10”), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The three levels of the fair value hierarchy are described below:
	Level 1		Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2		Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3		Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Pursuant to ASC 825, Financial Instruments, the fair value of cash and marketable securities is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.
	Assets measured at fair value on a recurring basis were presented on the Company’s balance sheets as of December 31, 2013.
	Fair Value Measurements as of December 31, 2013 Using:
			Total Carrying Value as of 12/31/13		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
					(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity securities		$	100,000	$	100,000	$	—	$	—
	Total		$	100,000	$	100,000	$	—	$	—
	Equity securities at December 31, 2013 comprise 200,000,000 shares of common stock of CleanPath Resources Corp. (CLNP.PK) recorded at fair value of $100,000 ($0.0005 per share).
	Concentration of credit risk – Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.
	Advertising costs - Advertising costs are anticipated to be expensed as incurred; however there were no advertising costs included in general and administrative expenses for the period ended December 31, 2013.
	Income taxes – The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more-likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.
	The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance.
	Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.
	Recent Accounting Pronouncements – The Company has evaluated recent pronouncements through Accounting Standards Updates (“ASU”) 2014-06 and believes that none of them will have a material impact on the Company’s financial position, results of operations or cash flows.

Going_Concern

Going Concern	9 Months Ended
	Dec. 31, 2013
Going Concern	'
Going Concern	'
	3	GOING CONCERN
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had a deficit accumulated during the development stage of $18,279 as of December 31, 2013. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.
	In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

Income_Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	4	INCOME TAXES
			The Company provides for income taxes under FASB ASC 740, Accounting for Income Taxes. FASB ASC 740 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect currently.
	FASB ASC 740 requires the reduction of deferred tax assets by a valuation allowance, if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is $4,570 which is calculated by multiplying a 25% estimated tax rate by the cumulative net operating loss (NOL) adjusted for the following items:
			2013
	Net loss for the year		$	18,279
	Adjustments			—
	Tax loss for the year			18,279
	Estimated effective tax rate			25	%
	Deferred tax asset		$	4,570
	The total valuation allowance is $4,570 as of December 31, 2013. Details are as follows:
			2013
	Deferred tax asset		$	4,570
	Valuation allowance			(4,570	)
	Current taxes payable			—
	Provision for income tax		$	—
	Below is a chart showing the estimated corporate federal net operating loss (NOL) and the year in which it will expire.
	Year				Amount		Expiration
		2013			$	18,279		2033

StockHolders_Equity

StockHolders' Equity	9 Months Ended
	Dec. 31, 2013
Stockholders Equity	'
StockHolders' Equity	'
	5		STOCKHOLDERS’ EQUITY
	Preferred Stock – The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of
	December 31, 2013, no shares of preferred stock had been issued.
	Common Stock - The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock. As of December 31, 2013, 12,041,667 shares were issued and outstanding.
	Upon formation of the Company on April 19, 2013, the Board of Directors issued 10,000,000 shares of common stock for $1,000 in services to the founding shareholder of the Company. In addition, the founding shareholder made a contribution of $749 to the Company which is recorded as additional paid in capital.
	On October 1, 2013, the Company issued 41,667 shares of its common stock for $5,000 in cash ($0.12 per share). The shares were sold to Ferris Holding, Inc., the controlling stockholder of the Company.
	On October 21, 2013, the Company entered into an Asset Purchase Agreement with BioSwan, Inc., a Nevada corporation (“BioSwan”), pursuant to which the Company acquired certain of the assets of BioSwan (collectively, the “Assets”), consisting of the following:
		·	A License Agreement between BioSwan and CleanPath Resources Corp, a Nevada corporation (“CleanPath”) dated as of March 26, 2013, relating to the Ferris Holding, Inc. proprietary primitive cell enhancing product and name NutraLoadTM (the “CleanPath Product Agreement”);.
		·	A License Agreement between the BioSwan and CleanPath dated as of July 16, 2013, relating to the Ferris trade secrets relating to Ferris Holding, Inc.’s proprietary AgronifierTM processes, materials, equipment, software, and hardware (the “CleanPath Technology Agreement”);
		·	Several non-disclosure agreements between BioSwan and various individuals; and
		·	Stock certificates for 200,000,000 shares of CleanPath common stock.
	Pursuant to the Asset Purchase Agreement, the Company issued 2,000,000 shares of its restricted common stock to BioSwan as full consideration for the Assets purchased.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Related Party Transactions	'
	6		Related Party transactions
	Advances from Ferris Holding, Inc., the controlling shareholder of the Company, are non-interest bearing, unsecured and due on demand.
	Upon formation of the Company on April 19, 2013, the Board of Directors issued 10,000,000 shares of common stock for $1,000 in services to the founding shareholder of the Company. In addition, the founding shareholder made a contribution of $749 to the Company which is recorded as additional paid in capital.
	On October 1, 2013, the Company issued 41,667 shares of its common stock for $5,000 in cash ($0.12 per share). The shares were sold to Ferris Holding, Inc., the controlling stockholder of the Company.
	On October 21, 2013, the Company entered two license agreements with Ferris Holding, Inc., a Nevada corporation (“Ferris”), the majority shareholder of the Company:
		1)	Pursuant to the first agreement (the “Product Agreement”), Ferris granted a license to the Company to Ferris’s proprietary stem cell enhancing product..  As consideration for the rights granted under the Product Agreement, the Company agreed to pay a royalty of 5% of the gross revenues royalties received from the sales of all products produced and sold by the Company pursuant to the rights granted under this license agreement.  The term of the agreement is initially for six months, and the parties may agree to renew the agreement.
		2)	Pursuant to the second agreement, the (“Technology Agreement”), Ferris granted a license to the Company to Ferris’s trade secrets relating to Ferris’s proprietary AgronifierTM processes, materials, equipment, software, and hardware (the “Agronifier Technology”), limited to the treatment of foods, supplements and liquids.  As consideration for the rights granted under the Product Agreement, the Company agreed to pay a royalty of 5% of the gross revenue from all products produced which incorporate the Technology, as well as from the provision of any services using the Technology from which revenues are generated.  The term of the agreement is initially for six months, and the parties may agree to renew the agreement.
	Bioexperience Ltd.
	Effective November 26, 2013, Bioexperience Ltd., a Nevada corporation controlled by Gerald A. Epling, the President and CEO of BioAdaptives, assigned to the Company Trademark Application No. 86021556, for use of “BioAdaptives” with respect to use for nutritional supplements.

Commitment

Commitment	9 Months Ended
	Dec. 31, 2013
Commitment	'
Commitment	'
	7	COMMITMENT
	The Company is committed to lease payments for office premises of $850 per month from January 1, 2014 to March 31, 2014.

Subsequent_Events

Subsequent Events	9 Months Ended
	Dec. 31, 2013
Subsequent Events	'
Subsequent Events	'
	8	SUBSEQUENT EVENTS
	On January 10, 2014, the U.S. Securities and Exchange Commission declared effective a registration statement filed by the Company (SEC File No. 333-192619). The registration statement registered the dividend distribution by Hemp, Inc., of shares of the Company’s common stock to the stockholders of Hemp.
	Assignment of Trademark
	On March 26, 2014, Gerald Epling assigned to the Company Trademark Application No. 86191161, for use of “BioAdaptives” with respect to educational services.

Summary_Of_Significant_Policie1

Summary Of Significant Policies (Policies)	9 Months Ended
	Dec. 31, 2013
Summary Of Significant Policies Policies	'
Consolidation	'
	Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its 100% owned subsidiary, Blenders Choice Inc. All inter-company balances and transactions have been eliminated. The Company and its subsidiary will be collectively referred to herein as the “Company.”
Use Of Estimates	'
	Use of estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S.GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash And Cash Equivalents	'
	Cash and cash equivalents – Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high credit quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value.
Investment Securities	'
	Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.
	In accordance with Accounting Standards Codification (“ASC”) 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Corporation. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.
Revenue Recognition	'
	Revenue Recognition – Revenue is only recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price to the buyer is fixed or determinable, and (4) collectability is reasonably assured.
Earnings (Loss) Per Share	'
	Earnings (loss) per share – Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. There were no potentially dilutive securities outstanding during the periods presented.
Stock-Based Compensation	'
	Stock-based compensation – The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Financial Accounting Standards Board (“FASB”) ASC 718-10, Compensation – Stock Compensation, and the conclusions reached by FASB ASC 505-50, Equity – Equity-Based Payments to Non-Employees. Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earliest of a performance commitment or completion of performance by the provider of goods or services as defined by FASB ASC 505-50.
Fair Value Of Financial Instruments	'
	Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 (“ASC 820-10”), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The three levels of the fair value hierarchy are described below:
	Level 1	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2	Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3	Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).
	Pursuant to ASC 825, Financial Instruments, the fair value of cash and marketable securities is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.
	Assets measured at fair value on a recurring basis were presented on the Company’s balance sheets as of December 31, 2013.
	Fair Value Measurements as of December 31, 2013 Using:
		Total Carrying Value as of 12/31/13		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
				(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity securities	$	100,000	$	100,000	$	—	$	—
	Total	$	100,000	$	100,000	$	—	$	—
	Equity securities at December 31, 2013 comprise 200,000,000 shares of common stock of CleanPath Resources Corp. (CLNP.PK) recorded at fair value of $100,000 ($0.0005 per share).
Concentration Of Credit Risk	'
	Concentration of credit risk – Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.
Advertising Costs	'
	Advertising costs - Advertising costs are anticipated to be expensed as incurred; however there were no advertising costs included in general and administrative expenses for the period ended December 31, 2013.
Income Taxes	'
	Income taxes – The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more-likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.
	The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance.
	Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements – The Company has evaluated recent pronouncements through Accounting Standards Updates (“ASU”) 2014-06 and believes that none of them will have a material impact on the Company’s financial position, results of operations or cash flows.

Summary_Of_Significant_Policie2

Summary Of Significant Policies (Tables)	9 Months Ended
	Dec. 31, 2013
Summary Of Significant Policies Tables	'
Schedule Of Fair Value Of Measurements Of Assets On Recurring Basis	'
	Assets measured at fair value on a recurring basis were presented on the Company’s balance sheets as of December 31, 2013.
	Fair Value Measurements as of December 31, 2013 Using:
		Total Carrying Value as of 12/31/13		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
				(Level 1)		(Level 2)		(Level 3)
	Assets:
	Equity securities	$	100,000	$	100,000	$	—	$	—
	Total	$	100,000	$	100,000	$	—	$	—

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Dec. 31, 2013
Income Taxes Tables	'
Schedule Of Total Deferred Tax Asset	'
	The total deferred tax asset is $4,570 which is calculated by multiplying a 25% estimated tax rate by the cumulative net operating loss (NOL) adjusted for the following items:
			2013
	Net loss for the year		$	18,279
	Adjustments			—
	Tax loss for the year			18,279
	Estimated effective tax rate			25	%
	Deferred tax asset		$	4,570
Schedule Of Total Valuation Allowance	'
			2013
	Deferred tax asset		$	4,570
	Valuation allowance			(4,570	)
	Current taxes payable			—
	Provision for income tax		$	—
Schedule Of Estimated Corporate Federal Net Operating Loss	'
	Below is a chart showing the estimated corporate federal net operating loss (NOL) and the year in which it will expire.
	Year				Amount		Expiration
		2013			$	18,279		2033

Summary_Of_Significant_Policie3

Summary Of Significant Policies (Details) (USD $)	Dec. 31, 2013
Assets:	'
Equity Securities	$100,000
Total Carrying Fair Value As Of December 31,2013	'
Assets:	'
Equity Securities	100,000
Total	100,000
Quoted Market Prices In Active Market - Level 1	'
Assets:	'
Equity Securities	100,000
Total	100,000
Significant Other Observable Inputs - Level 2	'
Assets:	'
Equity Securities	'
Total	'
Significant Unobservable Inputs - Level 3	'
Assets:	'
Equity Securities	'
Total	'

Income_Taxes_Schedule_Of_Total

Income Taxes (Schedule Of Total Deferred Tax Asset) (Details) (USD $)	9 Months Ended
	Dec. 31, 2013
Income Taxes Schedule Of Total Deferred Tax Asset Details	'
Net Loss For The Year	($18,279)
Adjustments	'
Tax Loss For The Year	-18,279
Estimated Effective Tax Rate	25.00%
Deferred Tax Asset	$4,570

Income_Taxes_Schedule_Of_Total1

Income Taxes (Schedule Of Total Valuation Allowance) (Details) (USD $)	9 Months Ended
	Dec. 31, 2013
Income Taxes Schedule Of Total Valuation Allowance Details	'
Deferred Tax Asset	$4,570
Valuation Allowance	-4,570
Current Taxes Payable	'
Provision For Income Tax	'

Income_Taxes_Schedule_Of_Estim

Income Taxes (Schedule Of Estimated Corporate Federal Net Operating Loss) (Details) (USD $)	9 Months Ended
	Dec. 31, 2013
Income Taxes Schedule Of Estimated Corporate Federal Net Operating Loss Details	'
Net Loss For The Year	($18,279)
Estimated Expiration Year	'2033

Summary_Of_Significant_Policie4

Summary Of Significant Policies (Narrative) (Details) (Equity securities of CleanPath Resources Corp, USD $)	Dec. 31, 2013
Equity securities of CleanPath Resources Corp	'
Equity securities of Clean Path Resources Corp.par value	$0.00
Equity securities held	200,000,000

StockHolders_Equity_Narrative_

StockHolders' Equity (Narrative) (Details) (USD $)	9 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Oct. 21, 2013			Oct. 01, 2013	Apr. 20, 2014
		Common Stock	Common Stock			Common Stock	Common Stock
			Bio Swan Inc			Ferris Holding, Inc - Majority Shareholder	Board Of Directors
Shares issued to board of directors for compensation of services, shares	'	10,000,000	'			'	10,000,000
Shares issued to board of directors for compensation of services, value	$1,000	$1,000	'			'	$1,000
Contribution by related party, as additional paid in capital	749	'	'			'	749
Shares issued to Ferris Holding, Inc.for cash, shares	'	41,667	'			41,667	'
Shares issued to Ferris Holding, Inc.for cash, value	$5,000	$4	'			$5,000	'
Shares issued to Ferris Holding, Inc.for cash, par value	'	'	'			$0.12	'
Asset purchase agreement terms	'	'	'			'	'
				A License Agreement between BioSwan and CleanPath Resources Corp, a Nevada corporation (“CleanPath”) dated as of March 26, 2013, relating to the Ferris Holding, Inc. proprietary primitive cell enhancing product and name NutraLoadTM (the “CleanPath Product Agreement”);.
				·	A License Agreement between the BioSwan and CleanPath dated as of July 16, 2013, relating to the Ferris trade secrets relating to Ferris Holding, Inc.’s proprietary AgronifierTM processes, materials, equipment, software, and hardware (the “CleanPath Technology Agreement”);
				·	Several non-disclosure agreements between BioSwan and various individuals; and
				·	Stock certificates for 200,000,000 shares of CleanPath common stock.
Asset Purchase Agreement, shares	'	2,000,000	2,000,000			'	'

Related_Party_Transactions_Nar

Related Party Transactions (Narratives) (Details) (Licensing Agreement, Ferris Holding, Inc - Majority Shareholder)	0 Months Ended
	Oct. 21, 2013
Licensing Agreement | Ferris Holding, Inc - Majority Shareholder	'
Related party transactions agreement terms	'
	Company entered two license agreements with Ferris Holding, Inc., a Nevada corporation (“Ferris”), the majority shareholder of the Company:
		1)	Pursuant to the first agreement (the “Product Agreement”), Ferris granted a license to the Company to Ferris’s proprietary stem cell enhancing product and the name “NutraLoadTM.”  As consideration for the rights granted under the Product Agreement, the Company agreed to pay a royalty of 5% of the gross revenues royalties received from the sales of all products produced and sold by the Company pursuant to the rights granted under this license agreement.  The term of the agreement is initially for six months, and the parties may agree to renew the agreement.
		2)	Pursuant to the second agreement, the (“Technology Agreement”), Ferris granted a license to the Company to Ferris’s trade secrets relating to Ferris’s proprietary AgronifierTM processes, materials, equipment, software, and hardware (the “Agronifier Technology”), limited to the treatment of foods, supplements and liquids.  As consideration for the rights granted under the Product Agreement, the Company agreed to pay a royalty of 5% of the gross revenue from all products produced which incorporate the Technology, as well as from the provision of any services using the Technology from which revenues are generated.  The term of the agreement is initially for six months, and the parties may agree to renew the agreement.

Commitment_Narrative_Details

Commitment (Narrative) (Details) (Subsequent Event, Lease Agreements - January , 2014 to March 31, 2014, USD $)	3 Months Ended
	Mar. 31, 2014
Subsequent Event | Lease Agreements - January , 2014 to March 31, 2014	'
Future lease payment for office premises per month	$850